eBay Inc. (NASDAQ:EBAY) [Trend Analysis] knocking active thrust in leading trading session, shares a loss of -0.26% to 30.64 with around 8.5 Million shares have changed hands in this session. Bronstein, Gewirtz& Grossman, LLC reminded that investors that a class action lawsuit has been filed against PayPal Holdings, Inc. (PYPL), eBay, Inc. (EBAY), and certain of its officers, and is on behalf of a class consisting of all persons or entities who: (1) purchased or otherwise acquired eBay securities on the open market on or after December 19, 2013 and subsequently received PayPal securities pursuant to eBay’s spin-off of PayPal, effective as of July 17, 2015; and/or (2) purchased or otherwise acquired PayPal securities on the open market between July 20, 2015 and April 28, 2016, both dates inclusive.
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) PayPal’s Venmo service was involved in unfair trade practices; (2) once the above facts were made public, it was likely to impact PayPal’s profitability of its Venmo service and increase regulatory scrutiny and/or; and (3) consequently, PayPal’s public statements were materially false and misleading at all relevant times. The stock is going forward its fifty-two week low with 42.38% and lagging behind from its 52-week high price with -7.68%.
Similar, the positive performance for the quarter recorded as -5.78% and for the year was 17.44%, while the YTD performance remained at 3.20%. EBAY has Average True Range for 14 days of 0.56.
Shares of Prima Biomed Ltd. (NASDAQ:PBMD) [Trend Analysis] swings enthusiastically in regular trading session, it a gain of 2.02% to close at $2.53. Prima BioMed Ltd (NASDAQ:PBMD) reported that the submission titled “TACTI-mel, Two ACTive Immunotherapies in Melanoma: Combination of IMP321 with an Anti-PD-1 Antagonist in a Phase I Trial” has been accepted for a presentation at the 2nd Annual Cancer Immunotherapy Conference, part of 24th International Molecular Medicine Tri-Conference, in San Francisco, California, between February 20 – 22, 2017.
Prima’s Chief Medical & Scientific Officer, Dr Frédéric Triebel, will deliver the presentation between 12:00pm – 12:30pm on Monday, February 20, which will be based on the pre-clinical results for the anti-PD-1/IMP321 combination and TACTI-mel trial design. The stock is going forward its fifty-two week low with 48.82% and lagging behind from its 52-week high price with -38.79%. PBMD last month stock price volatility remained 11.31%.